KLISBio
Silk innovation for life sciences
Silk innovation for life sciences
KLISBio is a clinical-stage regenerative medicine company, specializing in developing innovative technology platforms using natural silk fibroin. Silk fibroin, a widely recognized material in medicine, is biocompatible and promotes cell proliferation, thus stimulating in-vivo tissue regeneration. KLISBio's assets under development include vascular graft, bone graft substitutes, rotator cuff repair, and the flagship product SILKBridge, a silk-based nerve repair technology, slated for commercial launch in the US. Founded in 2014, KLISBio operates in the Biotechnology, Health Care, Life Sciences, and Medical Devices industries. The company received a Grant investment on 28 February 2024.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | Unknown | - | 28 Feb 2024 | |
| Convertible Note | Unknown | - | 27 Apr 2023 | |
| Convertible Note | Unknown | - | 26 Nov 2021 | |
| Series A | Unknown | - | 21 Apr 2016 | |
| Convertible Note | Unknown | - | 11 Dec 2015 |
We care about your data, and we'd love to use cookies make your experience better.
